Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16604684 | 0.78 | MCHR1 (0.33) | — | |
| SCHEMBL16604681 | 0.78 | IRAK4 (0.43) | IRAK4 | |
| SCHEMBL16604690 | 0.73 | CHRM4 (0.39) | IRAK4CHRM4ALDH1A1KDM4E | |
| SCHEMBL26865993 | 0.70 | — | — | |
| SCHEMBL16604691 | 0.66 | IKBKB (0.37) | ALDH1A1TP53KDM4E | |
| SCHEMBL16604680 | 0.65 | — | — | |
| SCHEMBL23334818 | 0.62 | IRAK4 (0.41) | IRAK4ALDH1A1TP53GFERKDM4E | |
| SCHEMBL7357755 | 0.59 | MCHR1 (0.43) | IRAK4KDM4E | |
| SCHEMBL7364277 | 0.59 | MCHR1 (0.40) | ALDH1A1KDM4E | |
| SCHEMBL16604731 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170035766-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS INC (US) | 2017-02-09 | — | — | US | disclosed |
| US-9518065-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-20150094305-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. | 2015-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170035766-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885CHRM4 4550/4885ALDH1A1 4076/4885 |
| US-20150094305-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885CHRM4 4550/4885ALDH1A1 4076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.